Introduction
============

Histologic determination in advanced non-small cell lung cancer (NSCLC) has only recently become a fundamental consideration in guiding treatment decisions [@b1]. The most common histologic subtypes of NSCLC, which accounts for an estimated 85% of lung cancers, are adenocarcinoma (∼30--50% of cases), squamous cell carcinoma (∼30% of cases), and large cell carcinomas (∼10% of cases) [@b2]. Historically, squamous cell carcinomas had been the predominant subtype but were supplanted by adenocarcinomas, likely reflecting changes related to the composition of cigarettes [@b2].

NSCLC-directed targeted therapies introduced into clinical practice over the past decade are mainly applicable to the treatment of patients with adenocarcinomas. These include the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) gefitinib (Iressa®, AstraZeneca; Wilmington, DE) [@b3] and erlotinib (Tarceva®, Genentech; South San Francisco, CA) [@b4] and the anaplastic lymphoma kinase (ALK) inhibitor crizotinib (Xalkori®, Pfizer; New London, CT) [@b5]. Underlying aberrations conferring response to these agents (i.e., *EGFR* mutations and *ALK* gene rearrangements, the presence of which are to be confirmed by molecular analysis) are predominantly seen in adenocarcinomas [@b1],[@b6]. Additionally, the anti-vascular endothelial growth factor (VEGF) monoclonal antibody bevacizumab (Avastin®, Genentech; South San Francisco, CA) [@b7] is approved specifically for nonsquamous NSCLC because of heightened bleeding-related safety issues among patients with squamous tumors [@b8],[@b9], an observation that has extended to some small molecule inhibitors, including sorafenib (Nexavar®, Bayer; Leverkusen, Germany) [@b10], sunitinib (SU11248, Sutent®, Pfizer; New London, CT) [@b11], and motesanib (Amgen; Thousand Oaks, CA) [@b12].

With the lack of applicability of the newest agents for treating NSCLC, squamous NSCLC poses unique challenges in the clinic and is being recognized as a subset with particularly high need for new therapies. Among tumors classified as squamous NSCLC, heterogeneity in angiogenic and proliferative behavior has been described [@b13]. To date, identifying serum tumor markers and growth factors with prognostic relevance specifically in squamous NSCLC has proved to be an elusive goal [@b14]. However, there is accumulating evidence that points toward a role for inhibiting the angiogenic fibroblast growth factor (FGF)/FGF receptor (FGFR) signaling pathway in squamous NSCLC [@b15]--[@b17]. Following an overview of the FGF/FGFR signaling pathway, this article discusses key observations regarding its role in the development and progression of NSCLC and opportunities for its therapeutic inhibition in NSCLC, particularly for squamous cell disease.

Overview of FGF and FGFRs
=========================

Biology and hallmarks
---------------------

FGFs belong to a family of highly conserved polypeptide growth factors [@b18],[@b19]. Most of the FGFs have a similar internal core structure, consisting of six identical amino acid residues and 28 highly conserved residues, with 10 of the latter interacting with the FGFRs [@b19]. Each of the four FGF tyrosine kinase receptors (FGFR1, FGFR2, FGFR3, and FGFR4) contains an extracellular component of three immunoglobulin-like domains (Ig-like I--III), a transmembrane domain, and an intracellular tyrosine kinase domain responsible for signal transmission to the cellular interior [@b18],[@b19]. Alternative splicing in Ig-like III of FGFR1 through three results in isoforms with varying degrees of binding specificity; FGFR IIIb and IIIc isoforms are mainly epithelial and mesenchymal, respectively [@b18],[@b19]. When FGFs bind to the FGFRs, dimerization results from a complex of two FGFs, two FGFRs, and two heparin sulfate chains (Fig. [1](#fig01){ref-type="fig"}) and ultimately leads to FGFR activation, with the adaptor protein FGFR substrate two serving to recruit the Ras/mitogen-activated protein kinase (MAPK) and phosphoinositide-3 kinase (PI3K)/protein kinase B (Akt) pathways [@b18].

![FGFR structure and function. FGFRs are single-pass transmembrane receptor tyrosine kinases consisting of an extracellular Ig-like domain and an intracellular split tyrosine domain. Upon ligand binding, FGFRs dimerize, resulting in transphosphorylation and activation of downstream signaling cascades. After activation, the receptor complex is internalized by endocytosis and degraded by lysosomes. Reproduced with permission from Wesche and colleagues 2011 [@b18], *Biochem J*, 437:199-213 © the Biochemical Society. FGFR, fibroblast growth factor receptor; FGF, fibroblast growth factor; HSPG, heparan sulfate proteoglycan.](cam40003-0681-f1){#fig01}

Genetics of FGFRs
-----------------

A total of 22 *FGF* genes have been identified in humans, of which the chromosomal locations have been established with one exception (*FGF16*) [@b19]. Clustering within the genome (e.g., *FGF3*, *FGF4*, and *FGF19*, all on chromosome 11q13, and both *FGF6* and *FGF23* on chromosome 12p13) illustrates formation of the FGF family via gene and chromosomal duplication and translocation [@b19]. *FGFR* mutations have been associated with developmental disorders and identified across a number of malignancies, including lung cancer (Table [1](#tbl1){ref-type="table"}) [@b18]. In addition to somatic *FGFR1* and *FGFR2* mutations (Table [1](#tbl1){ref-type="table"}), *FGFR4* mutations have been observed in lung adenocarcinoma with a potential contributing role to carcinogenesis [@b20],[@b21]. In a Japanese study of *FGFR4* mutations and polymorphisms in surgically resected NSCLC, there were no *FGFR4* mutations in the analyzed samples per direct sequencing [@b22]. However, when applying a genotyping assay, homozygous or heterozygous *FGFR4* Arg388 allele was present in 61.8% of patients.

###### 

FGFR aberrations identified in human cancer.[1](#tf1-1){ref-type="table-fn"}

  Cancer                                                Receptor          Aberration                                   Estimated prevalence                 Association with other syndromes            Molecular consequence
  ----------------------------------------------------- ----------------- -------------------------------------------- ------------------------------------ ------------------------------------------- ---------------------------------------------
  Breast                                                FGFR1             8p11-12 amp                                  ∼10% [@b18]                          Not known                                   Amplification of *FGFR1*
  Bladder                                               FGFR3             R248C                                        5--20% [@b71]--[@b80]                TDI                                         Enhanced kinase activity
  FGFR3                                                 S249C             25--69% [@b71]--[@b82]                       TDI                                  Enhanced kinase activity                    
  FGFR3                                                 G370/372C         2--9% [@b71]--[@b81]                         TDI                                  Enhanced kinase activity                    
  FGFR3                                                 S371/373C         1--4% [@b71]--[@b73],[@b76],[@b79],[@b80]    TDI                                  Enhanced kinase activity                    
  FGFR3                                                 Y373/375C         9--30% [@b71]--[@b81]                        TDI                                  Enhanced kinase activity                    
  FGFR3                                                 G380/382R         \<1--4% [@b71]--[@b73],[@b80],[@b82]         ACH                                  Enhanced kinase activity                    
  FGFR3                                                 A391/393E         \<1--1% [@b71],[@b73],[@b75],[@b81],[@b82]   CS                                   Enhanced kinase activity                    
  FGFR3                                                 K650/652E/Q/M/T   \<1--6% (E),                                 TDI, TDII, HCH, SADDAN, AN           Enhanced kinase activity                    
  \<1--2% (Q),                                                                                                                                                                                          
  1--3% (M),                                                                                                                                                                                            
  \<1% (T) [@b71],[@b74]--[@b77],[@b79],[@b81],[@b82]                                                                                                                                                   
  Prostate                                              FGFR3             S249C                                        \<1--6% [@b83],[@b84]                TDI                                         Enhanced kinase activity
  FGFR3                                                 A391E             \<1--2% [@b83],[@b84]                        CS                                   Enhanced kinase activity                    
  Endometrial                                           FGFR2             S252W                                        4--6% [@b85]--[@b87]                 AS                                          Altered ligand specificity
  FGFR2                                                 P253R             3% [@b85]                                    AS                                   Altered ligand specificity                  
  FGFR2                                                 N549K             3--4% [@b86],[@b87]                          Not known                            Enhanced kinase activity                    
  FGFR2                                                 K659N             1% [@b85]--[@b87]                            CR                                   Enhanced kinase activity                    
  Lung                                                  FGFR1             8p12 amp                                     11--20% (SSC) [@b35],[@b88],[@b89]   Not known                                   Amplification of *FGFR1*
  FGFR2                                                 W290C             2--3% [@b85],[@b90],[@b91]                   PS                                   Not known[2](#tf1-2){ref-type="table-fn"}   
  Rhabdomyosarcoma                                      FGFR4             N535K                                        3% [@b92]                            Not known                                   Enhanced kinase activity
  FGFR4                                                 V550E             3% [@b92]                                    Not known                            Enhanced kinase activity                    
  Multiple myeloma                                      FGFR3             t(4:14) trans                                15--23% [@b93]--[@b96]               Not known                                   Overexpression of FGFR3
  FGFR3                                                 R248C             1--2% [@b93],[@b97]                          TDI                                  Enhanced kinase activity                    
  FGFR3                                                 K650/652M         \<1--5% [@b93],[@b98],[@b99]                 TDI, SADDAN                          Enhanced kinase activity                    
  Brain                                                 FGFR1             N56K                                         5% [@b100]                           Not known                                   Enhanced kinase activity
  FGFR1                                                 K656E             NA                                           Not known                            Enhanced kinase activity                    
  Head and neck                                         FGFR3             R248C                                        5% [@b101]                           TDI                                         Enhanced kinase activity
  FGFR3                                                 S249C             1% [@b102]                                   TDI                                  Enhanced kinase activity                    
  FGFR3                                                 G697C             NA                                           Not known                            Enhanced kinase activity                    
  Melanoma                                              FGFR2             I642V                                        1% [@b103]                           Not known                                   Reduced kinase activity
  EMS                                                   FGFR1             8p11-12 trans                                100% [@b104]                         Not known                                   Constitutively active FGFR1-fusion proteins

FGFR, fibroblast growth factor receptor; amp, amplification; TDI/II, thanatophoric dysplasia I/II; ACH, achondroplasia; CS, Crouzon syndrome; HCH, hypochondroplasia; SADDAN, severe achondroplasia with developmental delay and acanthosis nigricans; AN, acanthosis nigricans; AS, Apert syndrome; CR, craniosynostosis; SCC, squamous cell carcinoma; PS, Pfeiffer syndrome; trans, translocation; NA, not available; EMS, 8p11 myeloproliferative disorder. The table, except for the column "Estimated prevalence" was reproduced with permission from Wesche and colleagues 2011 [@b18], *Biochem J*, 437:199-213 © the Biochemical Society.

Includes only the aberrations identified in human tumor samples.

FGFR2 W290G forms ligand-independent dimers.

Biologic effects of FGF signaling in normal physiology
------------------------------------------------------

FGF/FGFR signaling plays a role in stimulating cell proliferation and migration and promoting survival of various types of cells [@b18]. Overall, FGFs are key contributors to not only angiogenesis but also organogenesis, including the formation of the heart, lungs, limbs, nervous system, and mammary and prostate glands [@b18].

Role of the FGF Signaling Pathway in NSCLC
==========================================

Serum basic FGF (bFGF) levels have been shown to be increased in the NSCLC population (including both squamous cell and adenocarcinoma histologies) relative to healthy controls [@b23],[@b24]. In the past decade, research to elucidate the role of the FGF signaling pathway in NSCLC proliferation and differentiation has intensified. In one preclinical study performed with this research question in mind, Kuhn and colleagues found that intracellular levels and mRNA expression of bFGF correlated with the proliferation rate of all three NSCLC cell lines evaluated and that intracellular bFGF appears to function as an intrinsic growth factor in the setting of NSCLC [@b25].

There is a substantial and growing body of literature to support that the FGF signaling pathway interacts with and influences other signaling pathways involved in the development and progression of NSCLC. For example, the VEGF and FGF/FGFR pathways have been shown to act synergistically in promoting tumor angiogenesis [@b26], while an upregulation of bFGF was recently proposed as one of the mechanisms by which the janus kinase 2/signal transducer and activator of transcription 3 (JAK2/STAT3) pathway mediates tumor angiogenesis in NSCLC [@b27]. One in vitro series involving a newly developed squamous NSCLC line (SCC-35), in which there was a highly significant correlation between the overexpression of FGF3 and EGFR, supports that co-overexpression of both growth factors may be implicated in the pathogenesis of lung carcinoma [@b28]. Furthermore, cancer-associated fibroblasts and the FGF/FGFR signaling pathway have been implicated in the development of intrinsic and acquired resistance to EGFR TKIs in patients with NSCLC [@b29]--[@b32].

Interestingly, there appear to be some FGF/FGFR signaling pathway-related distinctions between NSCLC cases of squamous cell versus adenocarcinoma histology [@b15]--[@b17],[@b33],[@b34]. Recently, researchers from the Dana--Farber Cancer Institute (DFCI) and the Broad Institute described a high prevalence of *FGFR1* amplification specifically in squamous NSCLC, with amplification of a region of chromosome segment 8p11-12 (which includes the *FGFR1* gene) in 21% of squamous tumors versus 3% of adenocarcinomas (*P* \< 0.001) [@b15]. Similarly, a previously published German study had identified frequent and focal *FGFR1* amplification in squamous NSCLC but not other histologic subtypes of lung cancer [@b16], while Japanese researchers have since reported a significantly higher rate of increased *FGFR1* copy number in surgically resected squamous versus nonsquamous NSCLC (41.5% vs. 14.3%; *P* = 0.0066) [@b17]. However, there have been some reports to the contrary; for example, a recent German study designed to further elucidate the relevance of FGFR1 in lung cancer found that the proportion of samples displaying ≥4 copies of the *FGFR1* gene was numerically but not statistically higher for squamous versus adenocarcinoma histology (10.5% vs. 4.7%; *P* = 0.278) [@b35].

Accumulating evidence points to a role for FGF signaling in the disease invasion and metastasis characteristic of NSCLC [@b36],[@b37]. In a recent study focused on identifying angiogenesis-related microRNAs (miRs) altered in NSCLC, one miR (miR-155) was found to be significantly correlated with FGF2 in the overall cohort (*r* = 0.17; *P* = 0.002), but even more strongly in the subset with nodal disease (*r* = 0.34; *P* \< 0.001) [@b36].

FGFs/FGFRs have been identified as potential predictive and prognostic markers in NSCLC. In a number of studies, pretreatment bFGF levels have been correlated with prognosis in the NSCLC population [@b38]--[@b43]. In addition, recent evidence supports *FGFR1* amplification as an independent negative prognostic factor (while exhibiting a dose-dependent association with cigarette smoking) in patients with squamous NSCLC [@b44]. A series of studies by Brattström and colleagues yielded mixed findings, with elevated serum bFGF levels reported as a favorable prognostic factor in an early series [@b45], but as a negative prognostic factor in subsequent reports [@b38],[@b39]. One of the studies was based on samples from 58 patients with surgically resected NSCLC, in whom a number of variables (including bFGF, as well as tumor volume, platelet counts, and serum VEGF levels) were significant prognostic factors on univariate analysis, whereas significance was retained only for bFGF on multivariate analysis [@b38]. There was a significant correlation between bFGF and disease recurrence (*r* = 0.34; *P* = 0.01), with rates of 78% and 40% for patients with elevated and normal bFGF levels, respectively. Additionally, this study found a significant correlation between bFGF levels and VEGF levels (*r* = 0.44; *P* \< 0.001) and that the combination of growth factors was a significant prognostic factor on univariate but not multivariate analysis, although conclusions were confounded by the presence of elevated levels of both bFGF and VEGF in only six patients. In a Japanese retrospective analysis of predictors of long-term survival among 71 patients with surgically resected NSCLC of adenocarcinoma or squamous histology, mean bFGF levels were significantly higher in cases of metastatic nodal involvement and high levels were most strongly correlated with poor prognosis in patients also exhibiting high VEGF levels (*P* \< 0.0001) [@b42]. Per multivariate analysis, bFGF and VEGF levels were each independent prognostic factors regardless of histology. Adding complexity to the topic of FGF as a prognostic factor in NSCLC, the implications of increased FGF expression have been shown to differ based on its presence in tumor cells (negative prognostic marker) versus stroma (favorable prognostic marker) [@b46],[@b47], with stromal expression postulated to inhibit NSCLC progression [@b48]. From a predictive biomarker standpoint, data on the contribution of baseline FGF levels on response to treatment for NSCLC have been mixed, with some but not all studies supporting a potential role for FGF to predict for treatment outcomes in various settings (including but not limited to antiangiogenic regimens) [@b49]--[@b52].

Therapeutic Inhibition of FGF/FGFR Signaling
============================================

Preclinical observations in NSCLC
---------------------------------

A number of preclinical observations collectively suggest that FGF/FGFR signaling may be exploited as a therapeutic target in the NSCLC population. In the aforementioned DFCI study, in which 21% of squamous tumors exhibited *FGFR1* amplification, cell growth inhibition of an NSCLC line with focal *FGFR1* amplification was demonstrated via FGFR1-specific small hairpin ribonucleic acids (shRNAs) or small molecule inhibitors [@b15]. Earlier preclinical series had supported inhibitory activity against NSCLC for a number of different anti-FGF/FGFR therapies, including a bFGF-neutralizing monoclonal antibody, antisense oligonucleotides, or bFGF antisense cDNA-expressing vector in one study [@b25] and a dominant-negative FGFR1 IIIc-green fluorescent protein fusion protein or small molecule inhibitors in another study [@b53]. Additional preclinical data have described the antiangiogenic and antitumor activities of individual multitargeted small molecule inhibitors---specifically those for which the targets include FGF/FGFRs---against NSCLC; these include cediranib (Recentin™, AstraZeneca; Wilmington, DE) [@b54], nintedanib (BIBF 1120, Boehringer Ingelheim; Ingelheim, Germany) [@b55], pazopanib (Votrient™, GlaxoSmithKline; London, UK) [@b56], ponatinib (Iclusig®, ARIAD Pharmaceuticals, Inc, Cambridge, MA) [@b57], and a number of other investigational agents [@b16],[@b58]--[@b61]. Of note, inhibiting bFGF has been shown to increase the secretion of VEGF in NSCLC lines, supporting a therapeutic role for bFGF inhibition as a component of a multitargeted approach that also includes VEGF inhibition [@b62].

Clinical trials of FGF-targeting agents in NSCLC
------------------------------------------------

Ongoing clinical trials of FGFR-inhibiting multitargeted tyrosine kinases in advanced squamous NSCLC or advanced NSCLC in general, including but not limited to squamous histology, are summarized in Table [2](#tbl2){ref-type="table"}. Two multitargeted agents are being evaluated in a squamous-exclusive NSCLC population: (1) nintedanib, an inhibitor of VEGFR1 through 3, FGFR1 through 4, platelet-derived growth factor receptor (PDGFR) *α* and *β*, fms-related tyrosine kinase 3 (FLT-3), and members of the src family [@b55] and (2) ponatinib, a breakpoint cluster (BCR)--c-abl oncogene 1, nonreceptor tyrosine kinase (ABL) inhibitor (approved in December 2012 for treating two types of leukemia) that has also been shown to inhibit the four FGFRs, fueling research to determine its therapeutic potential as an FGFR inhibitor [@b57]. In an ongoing placebo-controlled phase I/II study, nintedanib is being added to gemcitabine/cisplatin as first-line treatment of advanced or recurrent NSCLC specifically of squamous histology (NCT01346540). An estimated 165 patients will be enrolled, with primary outcomes of adverse events and dose-limiting toxicities in phase I and progression-free survival in phase II. In a completed, open-label, phase I trial (*N* = 26, including three with squamous histology) of first-line nintedanib in combination with carboplatin/paclitaxel in advanced NSCLC, among seven patients with a confirmed partial response, two had squamous histology and one had mixed large cell/squamous histology [@b63]. The most commonly reported adverse events (occurring in ≥10% of patients) related to nintedanib were diarrhea (53.8%), fatigue (50.0%), and nausea (46.2%). For ponatinib, a phase II trial is underway in patients with advanced squamous NSCLC that had progressed after the most recent treatment regimen, also requiring that patients have confirmed *FGFR* kinase amplification or mutation per genotyping (NCT01761747). This trial has a target accrual of 40 patients and a primary endpoint of response. Orantinib (formerly TSU-68 and SU6688; Taiho Pharmaceutical Co. Ltd, Tokyo, Japan), an oral TKI that targets VEGFR2, PDGFR*β*, and FGFR1, was evaluated in a phase I trial (*N* = 37, including five patients with squamous NSCLC) in combination with carboplatin/paclitaxel as first-line therapy for advanced NSCLC, with 13 partial responses observed among 33 evaluable patients [@b64]. It was not specified as to whether any of these responses were in the squamous participants, and there are no known active clinical trials of this agent in advanced NSCLC as of this writing.

###### 

Ongoing trials[1](#tf2-1){ref-type="table-fn"} of multitargeted antiangiogenic tyrosine kinase inhibitors in squamous NSCLC

  Agent                                                                Phase                                                                                             Regimen                                                                                          Trial identifier
  -------------------------------------------------------------------- ------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------ ------------------
  General NSCLC (including squamous)[2](#tf2-2){ref-type="table-fn"}                                                                                                                                                                                                      
   Cediranib                                                           III                                                                                               Cediranib + first-line paclitaxel/carboplatin for advanced or metastatic NSCLC                   NCT00795340
   Nintedanib (BIBF 1120)                                              III                                                                                               Nintedanib + second-line docetaxel for locally advanced and/or metastatic, or recurrent NSCLC    NCT00805194
   Pazopanib                                                           II/III                                                                                            Pazopanib as maintenance therapy after first-line chemotherapy for advanced NSCLC                NCT01208064
  II                                                                   Pazopanib as second-line therapy after progression on bevacizumab-containing first-line therapy   NCT01262820                                                                                      
  II                                                                   Pazopanib + erlotinib as second- or third-line therapy for advanced NSCLC                         NCT01027598                                                                                      
  II                                                                   Pazopanib + paclitaxel as first-line therapy for advanced NSCLC                                   NCT01179269                                                                                      
  I                                                                    Pazopanib + vinorelbine in metastatic NSCLC or breast cancer                                      NCT01060514                                                                                      
   Dovitinib                                                           II                                                                                                Dovitinib after recent anti-VEGF therapy for advanced NSCLC or advanced colorectal cancer        NCT01676714
  Squamous-exclusive NSCLC                                                                                                                                                                                                                                                
   Ponatinib                                                           II/III                                                                                            Ponatinib for progressive squamous NSCLC or head and neck cancers with FGFR kinase alterations   NCT01761747
   Nintedanib (BIBF 1120)                                              I/II                                                                                              Nintedanib + first-line gemcitabine/cisplatin for advanced or recurrent squamous NSCLC           NCT01346540

NSCLC, non-small cell lung cancer; VEGF, vascular endothelial growth factor; FGFR, fibroblast growth factor receptor.

Includes trials indexed on ClinicalTrials.gov with a status of recruiting, not yet recruiting, or active, not recruiting, as of September 2013.

Phase I and II trials are included only for agents that have not reached phase III development for advanced NSCLC.

As shown in Table [2](#tbl2){ref-type="table"}, two phase III trials have been initiated in NSCLC populations without exclusion of squamous cell histology, one of nintedanib plus docetaxel as second-line therapy in advanced or recurrent NSCLC (LUME-Lung 1 \[NCT00805194\]) and the other of cediranib in combination with first-line paclitaxel/carboplatin for advanced NSCLC (CAN-NCIC-BR29 \[NCT00795340\]). Results of LUME-Lung 1 show improvement in the primary outcome of progression-free survival with nintedanib/docetaxel versus placebo/docetaxel in the entire study population (median, 3.4 vs. 2.7 months; *P* = 0.0019) as well as in the histologic subsets with squamous disease (*P* = 0.02) or adenocarcinoma (*P* = 0.02) [@b65]. Significant improvement in overall survival (OS) was also observed in the nintedanib group among patients with adenocarcinoma histology (median, 12.6 vs. 10.3 months with placebo plus docetaxel; *P* = 0.0359). Cediranib primarily targets VEGFR2 but has demonstrated some inhibitory activity against FGF-induced proliferation, albeit 275-fold less selective than its inhibition of VEGF-induced proliferation [@b54]. A prior phase II trial (CAN-NCIC-BR24) found that cediranib (using a higher dose than in the phase III CAN-NCIC-BR29 trial above) plus paclitaxel/carboplatin was not tolerable. However, compared with other histologies, the squamous participants did not have an increased risk of severe pulmonary hemorrhage or adverse efficacy outcomes, which included the primary endpoint of progression-free survival [@b66]. Regarding new-onset cavitation, 10 of 40 cases among cediranib recipients and seven of 23 cases among placebo recipients were in patients with squamous tumors.

The EGFR-directed monoclonal antibody cetuximab (ERBITUX®, ImClone; New York, NY) [@b67] is another targeted therapy that is currently under clinical evaluation for squamous NSCLC. A phase II trial investigated first-line cetuximab in combination with platinum-based chemotherapy in advanced or recurrent NSCLC (eLung \[NCT00828841\]; squamous or nonsquamous disease), with OS as the primary endpoint. Presented results showed that median OS with cetuximab-containing chemotherapy was significantly longer in patients with nonsquamous versus squamous disease (9.9 vs. 8.7 months; *P* = 0.0082) [@b68]. A phase III study is currently recruiting patients with advanced NSCLC of any histology (including squamous) to receive carboplatin/paclitaxel with or without bevacizumab and/or cetuximab (NCT00946712).

Finally, there are ongoing clinical investigations of other FGF/FGFR-targeted agents in advanced malignancies, although not specific to NSCLC or squamous NSCLC. The pan-FGFR inhibitors AZD4547 (AstraZeneca; Wilmington, DE; NCT01213160) and BGJ398 (Novartis; Cambridge, MA; NCT01004224; NCT01697605) are being evaluated in a phase I trial for advanced solid tumors; for BGJ398, eligibility criteria include confirmed FGFR-related alterations. A nonrandomized phase II trial of AZD4547 monotherapy is enrolling previously treated patients with *FGFR1*-amplified advanced squamous NSCLC (or *FGFR1*-amplified advanced breast cancer or *FGFR2*-amplified advanced esophagogastric cancer), with serial biopsies being performed to assess molecular effects (NCT01795768) [@b69]. Results are awaited from a phase I trial of the FGF ligand trap FP-1039 (FivePrime Therapeutics; South San Francisco, CA) in unresectable locally advanced or metastatic solid tumors (NCT00687505).

Future directions include studies to assess anti-FGF/FGFR agents in resectable disease (e.g., in combination with chemotherapy and/or radiation in the adjuvant setting), or even as a chemoprevention strategy [@b70]. Clinical trials to date have only investigated the efficacy of anti-FGF/FGFR agents in advanced NSCLC. Given the potential role of the FGF/FGFR signaling pathway in the pathogenesis of NSCLC, inhibition of this pathway in the adjuvant setting could provide benefit, especially for patients with squamous disease.

Conclusions
===========

While there have been several molecularly targeted agents developed for the treatment of nonsquamous NSCLC, there appears to be a unique opportunity to develop anti-FGF/FGFR-based regimens for the treatment of NSCLC of squamous histology. Recent research findings supporting a propensity for squamous NSCLC to exhibit increased *FGFR1* gene amplification strengthen the rationale for this novel approach. Multitargeted small molecule inhibitors that inhibit FGFR along with other angiogenic pathways/receptors are the most advanced in clinical development, although none have yet to reach phase III evaluation in squamous-exclusive NSCLC study populations. Further research efforts are needed to more fully characterize the manner by and degree to which FGF signaling influences the underlying biology of specific NSCLC histologies.
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